
|Articles|December 5, 2012
FDA updated Safety Communication: Ondansetron (Zofran) 32-mg, single IV dose pulled due to potential for serious cardiac risks
The 32-mg, single intravenous dose of the anti-nausea drug Zofran will no longer be marketed because of the potential for serious cardiac risk, according to an updated Safety Communication from FDA.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
GoodRx Offers Wegovy Weight-Loss Pill at Under $150 a Month
2
FDA Approves Denosumab-Mobz as Biosimilar for Prolia, Xgeva
3
COVID-19 Vaccination Reduces Mortality Related to COPD
4
Orforglipron Maintains Weight Loss After Discontinuation of Injectable GLP-1
5












































































































































































































